CAPR Deadline Alert: Levi & Korsinsky Reminds Capricor Therapeutics, Inc. (CAPR) Investors of Securities Class Action Deadline on September 28, 2026
A securities class action alleges Capricor Therapeutics did not follow the pre-specified blinding and protocol procedures for its Phase 3 HOPE-3 trial, with FDA later noting that the final study protocol deviated from the associated statistical analysis plan. NEW YORK, Sept. 2, 2026...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.